Oncotarget is a weekly medical journal covering various aspects. The journal was established in 2010 and is published by Impact Publishers. Oncotarget has been maintained as a traditional multidisciplinary journal with a primary focus on cancer research and oncology. Oncotarget also publishes papers in the fields of pathology, endocrinology physiology and age-related diseases. The research papers are published online in weekly issues with each issue being made available in print on demand.
The success of Oncotarget has come under the leadership of the most prominent scientists. At the helm of Oncotarget is Mikhail V. Blagosklonny who is a world-leading cancer research scientist. He serves as the monitoring editor with Andrei V. Gudkov as the editor in chief. Other members of the editorial board such as Andrew Schally (Nobel Prize winner) and Carlo M. Croce have published numerous papers in Oncotarget as well. Visit Oncotarget’s profile page at Facebook.
Oncotarget’s upcoming popularity comes as a result of constructive, peer-review aimed at helping the authors to increase the impact of their research. The journal’s target of making scientific results rapidly and widely available helps to maximize the impact of research by allowing exceptional discoveries to be shared quickly. Oncotarget also facilitates for insightful review while eliminating the border between specialties by linking different fields of biomedical science. In the long run, this fosters the application of science to fight diseases.
The journal also helps researchers contribute to the progress of science through the rapid publication of phenomenal research. When research is carried out, it often leads to the discovery of various concepts. Research in the field of medicine has seen a major increase therefore at Oncotarget the main aim of trying to learn more about cancer is slowly being achieved. Various new forms of treatment for cancer have been identified. Studies have helped in the development of drugs known as anti-cancer agents that have elements which fight the cancerous cells. Although specifically for different diseases, they have still been found useful in fighting cancer. These treatments, referred to as anti-cancer are similar to the anti-malarial and anti-epileptic drugs that patients take to not only alleviate symptoms but to avoid them all together. The journal is peer reviewed and is published by Impact Journals.